Literature DB >> 10793226

Surface-active properties of vasoactive intestinal peptide*.

H Onyüksel1, B Bodalia, V Sethi, S Dagar, I Rubinsteina.   

Abstract

The purpose of this study was to determine whether human vasoactive intestinal peptide (VIP) aggregates in aqueous solution and, if so, whether the peptide interacts with a biomimetic phospholipid monolayer and increases surface pressure. Using a custom-made Teflon trough containing HEPES buffer (pH 7.4) at room temperature and a surface tensiometer, we found that the critical micellar concentration (CMC) of VIP is 0.4 microM. Surface pressure of a dipalmitoylphosphatidylcholine (DPPC) monolayer spread over the HEPES buffer declined significantly over 120 min because of phospholipid decomposition. However, injection of VIP at concentrations above CMC into the subphase of the monolayer elicited a significant concentration-dependent increase in surface pressure that persisted for 120 min (P < 0.05). Unlike VIP, injection of [(8)Arg]-vasopressin at an equimolar concentration only prevented the time-dependent decline in DPPC monolayer surface pressure. Taken together, these data indicate that human VIP aggregates in aqueous solution and expresses surface-active properties at physiological concentrations in vitro. We suggest that these attributes could have a role in modulating the bioactive effects of the peptide in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10793226     DOI: 10.1016/s0196-9781(00)00161-3

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Solubilization of therapeutic agents in micellar nanomedicines.

Authors:  Lela Vuković; Antonett Madriaga; Antonina Kuzmis; Amrita Banerjee; Alan Tang; Kevin Tao; Neil Shah; Petr Král; Hayat Onyuksel
Journal:  Langmuir       Date:  2013-12-09       Impact factor: 3.882

2.  Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule.

Authors:  Shubha Priyamvada; Anoop Kumar; Seema Saksena; Hayat Onyuksel
Journal:  Nanomedicine (Lond)       Date:  2020-09-25       Impact factor: 5.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.